114 related articles for article (PubMed ID: 20587406)
1. Clinical updates on EGFR/HER targeted agents in early-stage breast cancer.
Macrinici V; Romond E
Clin Breast Cancer; 2010; 10 Suppl 1():E38-46. PubMed ID: 20587406
[TBL] [Abstract][Full Text] [Related]
2. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective.
Kulkarni S; Hicks DG
Ann Surg Oncol; 2008 Jun; 15(6):1677-88. PubMed ID: 18398661
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
4. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
6. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
7. Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer.
Guarneri V; Barbieri E; Dieci MV; Piacentini F; Conte P
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S62-6. PubMed ID: 21129613
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab.
Chan A; McGregor SR
Intern Med J; 2012 Mar; 42(3):267-74. PubMed ID: 21241440
[TBL] [Abstract][Full Text] [Related]
9. Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.
Goel S; Chirgwin J; Francis P; Stuart-Harris R; Dewar J; Mileshkin L; Snyder R; Michael M; Koczwara B
Breast; 2011 Apr; 20(2):101-10. PubMed ID: 21183347
[TBL] [Abstract][Full Text] [Related]
10. Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment.
Conte P; Guarneri V; Bengala C
Clin Breast Cancer; 2007 Dec; 7(11):841-9. PubMed ID: 18269773
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu role in breast cancer: from a prognostic foe to a predictive friend.
Ferretti G; Felici A; Papaldo P; Fabi A; Cognetti F
Curr Opin Obstet Gynecol; 2007 Feb; 19(1):56-62. PubMed ID: 17218853
[TBL] [Abstract][Full Text] [Related]
12. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
13. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
15. Facts and controversies in the use of trastuzumab in the adjuvant setting.
Dinh P; de Azambuja E; Cardoso F; Piccart-Gebhart MJ
Nat Clin Pract Oncol; 2008 Nov; 5(11):645-54. PubMed ID: 18779850
[TBL] [Abstract][Full Text] [Related]
16. Management and outcome of HER2-positive early breast cancer treated with or without trastuzumab in the adjuvant trastuzumab era.
Palmieri C; Shah D; Krell J; Gojis O; Hogben K; Riddle P; Ahmad R; Tat T; Fox K; Porter A; Mahmoud S; Kirschke S; Shousha S; Gudi M; Coombes RC; Leonard R; Cleator S
Clin Breast Cancer; 2011 Apr; 11(2):93-102. PubMed ID: 21569995
[TBL] [Abstract][Full Text] [Related]
17. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
Castrellon AB; Glück S
Clin Adv Hematol Oncol; 2008 Sep; 6(9):666-72. PubMed ID: 18827789
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]